Insight Molecular Diagnostics Inc. (IMDX)
| Market Cap | 174.37M |
| Revenue (ttm) | 1.95M |
| Net Income (ttm) | -47.84M |
| Shares Out | 32.29M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,257 |
| Open | 5.41 |
| Previous Close | 5.59 |
| Day's Range | 5.27 - 5.72 |
| 52-Week Range | 2.33 - 8.51 |
| Beta | 1.77 |
| Analysts | Buy |
| Price Target | 8.33 (+54.26%) |
| Earnings Date | Aug 10, 2026 |
About IMDX
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test ... [Read more]
Financial Performance
In 2025, IMDX's revenue was $4.06 million, an increase of 115.58% compared to the previous year's $1.88 million. Losses were -$50.22 million, -17.57% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for IMDX stock is "Buy." The 12-month stock price target is $8.33, which is an increase of 54.26% from the latest price.
News
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-
Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry
NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, the...
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced an online published article in the American Journal of Transplantation a...
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced it will be highlighting its GraftAssure™ technology at the upcoming Amer...
Insight Molecular Diagnostics Earnings Call Transcript: Q1 2026
GraftAssureDx FDA review is progressing, with first U.S. orders expected later this year. Q2 revenue is projected at $250,000 and cash burn to peak above $9 million before declining. International traction is building, and long-term gross margins are targeted at 70% or higher.
Insight Molecular Diagnostics Earnings release: Q1 2026
Insight Molecular Diagnostics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Insight Molecular Diagnostics Shareholder letter: Q1 2026
Insight Molecular Diagnostics has published a letter to shareholders covering Q1 2026, which was released on May 13, 2026.
Insight Molecular Diagnostics Quarterly report: Q1 2026
Insight Molecular Diagnostics has published its Q1 2026 quarterly earnings report on May 13, 2026.
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first t...
Insight Molecular Diagnostics Slides: Investor presentation
Insight Molecular Diagnostics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
iMDx to Release First Quarter 2026 Results on May 13, 2026
NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market...
Insight Molecular Diagnostics Proxy statement: Proxy filing
Insight Molecular Diagnostics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Insight Molecular Diagnostics Proxy statement: Proxy filing
Insight Molecular Diagnostics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Insight Molecular Diagnostics Transcript: 25th Annual Needham Virtual Healthcare Conference
Insight Molecular Diagnostics is advancing GraftAssure, a decentralized transplant rejection test using droplet digital PCR, with strong clinical data and a dual quantification approach. The company targets rapid U.S. and EU expansion, robust margins, and is positioned to benefit from new anti-rejection therapies.
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay
Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, Scotland T...
Insight Molecular Diagnostics Earnings Call Transcript: Q4 2025
GraftAssureDx was submitted to the FDA, with commercialization and adoption efforts accelerating, supported by strong transplant center engagement and favorable clinical data. Financially, a $26M raise and robust sales pipeline position the company for growth, while market trends and reimbursement improvements provide additional tailwinds.
Insight Molecular Diagnostics Shareholder letter: Q4 2025
Insight Molecular Diagnostics has published a letter to shareholders covering Q4 2025, which was released on March 26, 2026.
Insight Molecular Diagnostics Annual report: Q4 2025
Insight Molecular Diagnostics has published its Q4 2025 annual report on March 26, 2026.
Insight Molecular Diagnostics Earnings release: Q4 2025
Insight Molecular Diagnostics released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Insight Molecular Diagnostics submits GraftAssureDx for FDA review
The company said, “We are pleased to share that GraftAssureDx has become, to our knowledge, the first ever kitted dd-cfDNA assay to be submitted to the FDA for regulatory review.
Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year
Reports Q4 revenue $1.14M vs. $1.49M last year. The company said, “In 2026, we expect to continue to be thoughtful about capital allocation, hiring, and expense growth. We expect to…
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quart...
Insight Molecular Diagnostics Slides: Investor presentation
Insight Molecular Diagnostics has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the mar...
Insight Molecular Diagnostics highlights publication of study on GraftAssure
Insight Molecular Diagnostics (IMDX) highlighted the publication of a new peer-reviewed study demonstrating the potential superiority of the company’s GraftAssure assay technology. The study, publishe...